FTXH

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-218.8K ExitQ2 2025 $219k -- --
Ken GriffinCitadel Advisors $-218.8K ExitQ2 2025 $219k -- --
Ken GriffinCitadel Advisors $-345.9K ExitQ3 2024 $346k -- --
Ken GriffinCitadel Advisors $-345.9K ExitQ3 2024 $346k -- --

News

reuters.comTrump to announce discount drug pricing expansion, White House official saysreuters.comMay 18

marketwatch.comCould pressure to make money faster kill the next lifesaving pill?marketwatch.comApr 15

Trade FTXH

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.

IPO Date: Sep 22, 2016

Market Data

Open: $35.71
High: $35.71
Low: $35.09
Volume: 4.8K
Avg Volume: 8.3K
52W High: $36.28
52W Low: $25.37

Valuation

Market Cap: $34M
Dividend Yield: 42.1%

Financials

Financial statement snapshot is not available yet.

Events

DividendMar 26

$0.0573